NewAmsterdam Pharma Company NV
NASDAQ:NAMS
Intrinsic Value
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residua... [ Read More ]
The intrinsic value of one NAMS stock under the Base Case scenario is 1.06 USD. Compared to the current market price of 20.17 USD, NewAmsterdam Pharma Company NV is Overvalued by 95%.
Valuation Backtest
NewAmsterdam Pharma Company NV
Run backtest to discover the historical profit from buying and selling NAMS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
NewAmsterdam Pharma Company NV
| Current Assets | 389.3m |
| Cash & Short-Term Investments | 383.5m |
| Other Current Assets | 5.8m |
| Non-Current Assets | 81.8m |
| PP&E | 112k |
| Intangibles | 81.6m |
| Other Non-Current Assets | 93k |
| Current Liabilities | 38.3m |
| Accounts Payable | 20.9m |
| Other Current Liabilities | 17.5m |
| Non-Current Liabilities | 10.5m |
| Long-Term Debt | 23k |
| Other Non-Current Liabilities | 10.5m |
Earnings Waterfall
NewAmsterdam Pharma Company NV
|
Revenue
|
107.1m
EUR
|
|
Operating Expenses
|
-254m
EUR
|
|
Operating Income
|
-146.9m
EUR
|
|
Other Expenses
|
-11m
EUR
|
|
Net Income
|
-157.9m
EUR
|
Free Cash Flow Analysis
NewAmsterdam Pharma Company NV
NAMS Profitability Score
Profitability Due Diligence
NewAmsterdam Pharma Company NV's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
NewAmsterdam Pharma Company NV's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
NAMS Solvency Score
Solvency Due Diligence
NewAmsterdam Pharma Company NV's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
NewAmsterdam Pharma Company NV's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NAMS Price Targets Summary
NewAmsterdam Pharma Company NV
According to Wall Street analysts, the average 1-year price target for NAMS is 35.41 USD with a low forecast of 28.28 USD and a high forecast of 47.25 USD.
Ownership
NAMS Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
NAMS Price
NewAmsterdam Pharma Company NV
| Average Annual Return | 3.33% |
| Standard Deviation of Annual Returns | 15.5% |
| Max Drawdown | -66% |
| Market Capitalization | 1.7B USD |
| Shares Outstanding | 89 268 000 |
| Percentage of Shares Shorted | 0.85% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. The company is headquartered in Naarden, Noord-Holland. The company went IPO on 2022-11-23. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The firm is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The firm is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The firm strives to offer its products around the world.
Contact
IPO
Employees
Officers
The intrinsic value of one NAMS stock under the Base Case scenario is 1.06 USD.
Compared to the current market price of 20.17 USD, NewAmsterdam Pharma Company NV is Overvalued by 95%.
You don't have any saved screeners yet
